Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 14/20 | 0.75 |
| ▸ | MMP1 | P03956 | 11/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.74 |
| ▸ | PGR | P06401 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | IKBKB | O14920 | 1/20 | 0.72 |
| ▸ | CHUK | O15111 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123848 | 1.00 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL1301198 | 1.00 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL3836633 | 1.00 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL5912759 | 1.00 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL73249 | 0.99 | NR3C1 (0.76) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL2898449 | 0.99 | NR3C1 (0.76) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL15671680 | 0.99 | NR3C1 (0.76) | NR3C1MMP1CYP3A4PGRMEN1 | |
| Water SCHEMBL201856 | 0.98 | NR3C1 (0.75) | NR3C1MMP1CYP3A4PGRMEN1 | |
| Dexamethasone SCHEMBL3404392 | 0.95 | HIF1A (0.82) | NR3C1MMP1CYP3A4PGRMEN1 | |
| SCHEMBL11064010 | 0.94 | NR3C1 (0.72) | NR3C1MMP1CYP3A4PGRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5272139-A | Amelioration or elimination of postoperative pain | CARY GEORGE R JR (US) | 1993-12-21 | — | — | US | claimed |
| EP-0259983-A2 | The use of corticosteroids for amelioration or elimination of postoperative pain | Cary Jr., George R. (US) | 1988-03-16 | — | — | EP | claimed |
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7612115-B2 | Citric acid, polyethylene glycol, and ofloxacin; low gelation temperatures; bioavailability | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090012058-A1 | Prophylactic or Therapeutic Agents For Allergic Ophthalmic Diseases or Allergic Nasal Diseases, Comprising Tricyclic Triazolobenzazepine Derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1994931-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ALLERGIC OPHTHALMIC DISEASE OR ALLERGIC NASAL DISEASE COMPRISING TRICYCLIC TRIAZOLOBENZOAZEPINE DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1312366-B1 | GELLING AQUEOUS PHARMACEUTICAL COMPOSITIONS | WAKAMOTO PHARMA CO LTD (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20060172969-A1 | Aqueous pharmaceutical compositions | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1312366-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-5854384-A | Process for preparing poly-α-amino acid particles | SR CORPORATION (JP) | 1998-12-29 | — | — | US | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0259983-B1 | The use of corticosteroids for amelioration or elimination of postoperative pain | CARY GEORGE R JR (US) | 1995-02-15 | — | — | EP | disclosed |
| US-5272139-A | Amelioration or elimination of postoperative pain | CARY GEORGE R JR (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0259983-A2 | The use of corticosteroids for amelioration or elimination of postoperative pain | Cary Jr., George R. (US) | 1988-03-16 | — | — | EP | disclosed |
| EP-0108218-A2 | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility | VEREX LABORATORIES, INC. (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012058-A1 | Prophylactic or Therapeutic Agents For Allergic Ophthalmic Diseases or Allergic Nasal Diseases, Comprising Tricyclic Triazolobenzazepine Derivative | TRPC5, TPSAB1, TRPV1 | NR3C1 311/4885MMP1 351/4885CYP3A4 1988/4885 |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | MALT1, SLC10A2, LCP2 | NR3C1 1301/4885MMP1 1124/4885CYP3A4 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.